Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021

Publisher Name :
Date: 01-Dec-2021
No. of pages: 700
Inquire Before Buying

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies

Murine mAb

Chimeric mAb

Humanized mAb

Human aAb

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 provides the reader with the following key benefits:

In-depth understanding of monoclonal antibodies deal trends since 2014

Access to headline, upfront, milestone and royalty data

Access to the structure of monoclonal antibodies agreements

Comprehensive access to over 1100 actual monoclonal antibodies deals entered into by the world's biopharma companies

Identify the leading monoclonal antibody partnering companies

Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 includes:

Trends in monoclonal antibodies dealmaking in the biopharma industry since 2014

Access to headline, upfront, milestone and royalty data

Access to over 1100 monoclonal antibodies deal records

The leading monoclonal antibodies deals by value since 2014

Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014

In Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive access to available deals and contract documents for over 1100 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise monoclonal antibody rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2021

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Monoclonal antibody deals by company A-Z
Appendix 2 - Monoclonal antibody deals by stage of development
Appendix 3 - Monoclonal antibody deals by deal type
Appendix 4 - Monoclonal antibody deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Tables of Figures

Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2014
Figure 3: Active monoclonal antibody dealmaking activity since 2014
Figure 4: Monoclonal antibody partnering by deal type since 2014
Figure 5: Monoclonal antibody partnering by disease type since 2014
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2014
Figure 11: Most active monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
  • Global Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Antibody market size was valued at US$ 8893.3 million in 2023. With growing demand in downstream market, the Antibody is forecast to a readjusted size of US$ 12940 million by 2030 with a CAGR of 5.5% during review period. The research report highlights the growth potential of the global Antibody market. Antibody are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supp......
  • Global Antibody Production Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 121
    Antibody production involves preparation of antigen samples and their safe injection into laboratory or farm animals so as to evoke high expression levels of antigen-specific antibodies in the serum, which can then be recovered from the animal. Polyclonal antibodies are recovered directly from serum (bleeds). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (mil......
  • Global Antibody Production Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Antibody Production market: According to our latest research, the global Antibody Production market looks promising in the next 5 years. As of 2022, the global Antibody Production market was estimated at USD 9193.37 million, and it's anticipated to reach USD 17140.24 million in 2028, with a CAGR of 10.94% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global ......
  • Global Antibody Production Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 117
    Report Overview: The Global Antibody Production Market Size was estimated at USD 8847.90 million in 2022 and is projected to reach USD 14207.79 million by 2029, exhibiting a CAGR of 7.00% during the forecast period. This report provides a deep insight into the global Antibody Production market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key mark......
  • Global Anti-CD20 Monoclonal Antibodies Professional Survey Report 2023, Forecast to 2028
    Published: 30-Nov-2023        Price: US 3280 Onwards        Pages: 100
    Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all th......
  • Global Anti-CD20 Monoclonal Antibodies Market Research Report 2023, Forecast to 2028
    Published: 30-Nov-2023        Price: US 2680 Onwards        Pages: 165
    Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all th......
  • Monoclonal Antibody Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 92
    This study focuses on China's Monoclonal Antibody industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services.......
  • Monoclonal Antibody Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 73
    This study focuses on China's Monoclonal Antibody industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions......
  • Monoclonal Antibody Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 219
    China's demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, i......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs